Table 1.
Patient characteristics (sorted chronologically according to date of transplant)
| Pt | Sex/Age | Time Dx to SCT (yrs) | Diagnosis | Prior treatment (non-chemotherapy | Prior-treatment (chemotherapy) | Highest stage prior to HSCT | Disease status prior to HSCT | Conditioning regimen |
|---|---|---|---|---|---|---|---|---|
| 1 | F/57 | 2.8 | SS w/o large cell transformation (LCT) | B, C, EB, ECP, INF, Me, PUVA, S, Sar, Tacrolimus, TSEB | Alemtuzumab | IVA1 | Active disease, progressive | Flu/Cy |
| 2 | M/52 | 1.1 | MF w/o LCT | - | CHOP, HyperCVAD | IIB | CR | Flu/Bu |
| 3 | M/41 | 1.6 | Gamma-delta T-cell lymphoma (GDTL) | B, Hydroxychloroquine, S, TSEB | Denileukin Diftitox, HyperCVAD, Methotrexate | T3b | Active disease, chemo-responsive | Flu/Mel |
| 4 | F/43 | 0.8 | MF w/o LCT | S, INF, TSEB | - | IIB | MRD (marrow) | Cy/TBI |
| 5 | F/48 | 0.8 | GDTL | B, S | Alemtuzumab, Cytarabine, Cyclophosphamide, Methotrexate | T3b | Active disease, chemo-responsive | Cy/TBI |
| 6 | M/56 | 5.9 | MF with LCT | B, C, EB, Imiquimod, INF, M, S, TSEB, PUVA | Alemtuzumab, Denileukin Diftitox, ICE, Zanolimumab | IVA2 | Active disease, progressive | Flu/Bu |
| 7 | F/52 | 7.0 | MF with LCT | C, INF, Me, S, Tazarotene, TSEB, V | CHOP | IVB | CR | Flu/Bu |
| 8 | M/61 | 3.7 | MF w/o LCT | B, C, INF, PUVA, S, Sar, Tretinoin, TSEB, UVB | Alemtuzumab | IIIB | CR | Flu/Bu |
| 9 | F/44 | 3.9 | GDTL | B, EB, S, V | Cyclophosphamide, Denileukin Diftitox | T3b | Active disease, progressive | Flu/Bu |
| 10 | M/61 | 0.5 | SS with LCT | S, TSEB, UVB | CHOP, HyperCVAD, Alemtuzumab | IVA2 | Active disease, progressive | Flu/Bu |
| 11 | F/61 | 6.8 | SS w/o LCT | B, ECP, INF, M, PUVA, S, Sar, TSEB, V | Alemtuzumab | IVA2 | Active disease, chemo-responsive | Flu/Bu |
| 12 | F/54 | 6.8 | SS w/o LCT | B, ECP, Forodesine, INF, Pegfilgastrim, PUVA, Romidepsin, S, Tretinoin | Alemtuzumab | IVA2 | Active disease, chemo-responsive | Flu/Bu |
LCT = Large cell transformation
MF = Mycosis Fungoides
GDTL = Gamma-delta T-cell lymphoma
SS = Sézary Syndrome
TRM = Transplant-related mortality
B = Bexarotene
C = Carmustine (topical)
EB = Localized electron beam radiotherapy
ECP = Extracorporeal photopheresis
INF = Interferon-alpha/gamma
Me = Mechlorethamine (topical)
PUVA = Psoralen + Ultraviolet light A photochemotherapy
S = Steroids
Sar = Sargramostim
TSEB = Total skin electron beam radiation treatment
UVB = Ultraviolet light B phototherapy
V = Vorinostat